Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Thyroid Cancer Survivors Diagnosed Before 40 At Higher Risk For Aging-Related Disease
December 31st 2017Patients diagnosed with thyroid cancer before the age of 40 appear to be at the highest risk for age-related diseases, including heart disease and diabetes, compared with their age-matched counterparts.
3-D Simulation Helps Patients See Radiation Therapy Plan Firsthand
December 29th 2017The Virtual Environment Radiotherapy Training (VERT™) system, originally designed to teach medical students and physicians about administering radiation therapy, is being used to explain to people who have prostate cancer what their treatment will look like.
Foundation Continues Legacy to 'Never Give Up'
December 29th 2017The V Foundation for Cancer Research was founded by ESPN and legendary basketball coach Jim Valvano with one goal in mind: to achieve victory over cancer. Since its start in 1993, the V Foundation has awarded over $200 million in cancer research grants nationwide and has grown to become one of the premier supporters of cutting-edge cancer research funds.
Childhood Cancer Survivors at Increased Risk for High Blood Pressure
December 23rd 2017Approximately 420,000 Americans are adult survivors of childhood cancer, and these individuals may be twice as likely to have high blood pressure, also known as hypertension, according to researchers at St. Jude Children’s Research Hospital.
Blue Faery Helps Patients Spread Their Wings After Liver Cancer Diagnosis
December 21st 2017Blue Faery, the Adrienne Wilson Liver Cancer Association, is a nonprofit corporation founded in 2002, with the intent to prevent, treat and cure primary liver cancer – particularly HCC – through research, education and advocacy. Its name, inspired by Adrienne, has a unique background.
Elderly Patients Significantly Underrepresented in Hematology Clinical Trials
December 12th 2017Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.
Alternative Chemotherapy Dosing Strategies Improve Breast Cancer Outcomes
December 6th 2017For women with early-stage breast cancer who are receiving chemotherapy, shortening the time between treatment cycles or administering the agents sequentially may reduce disease recurrence and mortality compared with standard chemotherapy regimens.
Penn Medicine Launches Smoking Cessation Program
November 20th 2017Physicians at Penn Medicine’s Abramson Cancer Center in Philadelphia are ready to launch their new treatment program designed to help patients with cancer to quit smoking. The program is intended to provide patients with “state-of-the-science” tobacco use treatment, while also assisting patients with their medical treatment and recovery.
Cooking with Olive Oil: Lose Weight, Decrease Risk for Prostate Cancer Progression
November 17th 2017Data from a pilot study showed an added benefit from the incorporation of extra virgin olive oil into the diets of men with low-risk prostate cancer. As a result, this dietary modification could lead to weight loss, while also helping the body to absorb compounds with anticancer properties.